Program
Trazodone
Also written as “Trazodone HCl”, “Trazodone 20 mg” and “150 mg trazodone hydrochloride”.
Its studies are mostly in Depression · Diabetic Neuropathies · Depressive Disorder, Major · Sleep Wake Disorders, led by 4 companies.
Drug pageTrazodone: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Angelini Pharmaits history only | 50 open or running | phase 3since Mar 12, 2014 | Mar 12, 2014 | none ahead |
| Labopharm | 50 open or running | phase 3since Oct 17, 2008 | Oct 17, 2008 | none ahead |
| Lee's Pharmaceuticalits history only | 30 open or running | phase 3since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Targeted Medical Pharmaits history only | 10 open or running | phase 3since Nov 5, 2011 | Nov 5, 2011 | none ahead |
Also a collaborator on its studies: Chiltern International, Cross Research, eResearch Technology and Algorithme Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Labopharm only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2008First study: phase 3 study in Depressive Disorder, MajorFirst studyNCT00775203 · 412 enrolled · United States, Canada
- Feb 6, 2009Phase 1 study in HealthyNCT00839072 · 24 enrolled · Canada
- May 10, 20103 phase 1 studiesNCT01121926, NCT01121913, NCT01121900
TargetBeta
“Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Studies
All 5 Labopharm leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01121926Healthy Subjects | 1 | Completed | Mar 2008 | 30 |
| NCT01121913Healthy | 1 | Completed | Apr 2005 | 24 |
| NCT01121900Healthy | 1 | Completed | Jul 2008 | 26 |
| NCT00839072Healthy · Canada | 1 | Completed | Feb 2009 | 24 |
| NCT00775203Depressive Disorder, Major · United States, Canada | 3 | Completed | Nov 2007 | 412 |
How it is read
Names in the registry
- “Trazodone HCl”, 10 entries
- “Trazodone”, 3 entries
- “Trazodone 20 mg”, 2 entries
- “150 mg trazodone hydrochloride”, 1 entry
- “300 mg trazodone hydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Depression, 3 studies
- Diabetic Neuropathies, 2 studies
- Depressive Disorder, Major, 2 studies
- Sleep Wake Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.